ProceduresGovernment

Estrogens and Progestins

Código 293723 (Harmonized System 2012 by 6 digits)

 2023: US$96.9M, Total Trade Exchange

2023: US$64.9M, International Sales

  2023: US$31.9M, International Purchases

In 2023, the trade exchange (includes international purchases and sales) of Estrogens and Progestins was US$96.9M.

In 2022, the states with the most international sales in Estrogens and Progestins were Ciudad de México (US$36.7k).

The states with the most international purchases in 2023 were Ciudad de México (US$26.9M) and Estado de México (US$3.13M).

In 2022, the main commercial destinations of Estrogens and Progestins were Guatemala (US$36.7k) and United States (US$9).

The main commercial origins of Estrogens and Progestins in 2023 were Germany (US$21.1M), China (US$4.46M), Italy (US$3.21M), France (US$1.07M), and Netherlands (US$67.7k).

In the global context, the main exporting countries of Estrogens and Progestins in 2022 were China (US$242M), Italy (US$135M), and Netherlands (US$115M). In the same year, the main importing countries of Estrogens and Progestins were Netherlands (US$73.8M), Italy (US$66.7M), and United States (US$64.5M).

Trade Balance of Mexico

#permalink to section

Net Trade Balance

#permalink to section

US$96.9M, Total Trade Exchange (2023)

In 2023, the total trade exchange of Estrogens and Progestins in Mexico (including international purchases and sales) was US$96.9M.

The visualizations show the net balance of Estrogens and Progestins at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.

Net International Trade

#permalink to section

July, 2024

  • US$1.36M, International Purchases
  • US$4.93M, International Sales

In July 2024, international sales of Estrogens and Progestins were US$4.93M, while international purchases reached US$1.36M. The above results in a trade balance of US$3.58M.

Exchange by Territory

#permalink to section

International Sales

#permalink to section

Ciudad de México: US$36.7k, State with the Most International Sales (2022)

Guatemala: US$36.7k, Main commercial destination (2022)

In 2022, the states with the highest international sales in Estrogens and Progestins were Ciudad de México (US$36.7k).

In 2022, the countries with the most international purchases from Mexico were Guatemala (US$36.7k) and United States (US$9).

International Purchases

#permalink to section

Ciudad de México: US$26.9M, State with the Most International Purchases (2023)

Germany: US$21.1M, Main Commercial Origin (2023)

In 2023, the states with the highest international in Estrogens and Progestins were Ciudad de México (US$26.9M) and Estado de México (US$3.13M).

The countries with the most international sales to Mexico in 2023 were Germany (US$21.1M), China (US$4.46M), Italy (US$3.21M), France (US$1.07M), and Netherlands (US$67.7k).

Specialization

#permalink to section

Specialization by State

#permalink to section

The RCA-Complexity  diagram compares the Revelead Comparative Advantages of states in Estrogens and Progestins  and the Economic Complexity Index of each state.

RCA values ​​greater than 1 indicate that the state has comparative advantages in Estrogens and Progestins. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.

Origins and Trade Destinations

#permalink to section

  • 1.44%, Mexican share in global exports - 2022
  • 1.14%, Mexican share in global imports - 2022

The visualizations show the global market for Estrogens and Progestins. In both charts, Mexico stands out in order to identify its participation in the export and import market.

In 2022, the main exporting countries of Estrogens and Progestins were China (US$242M), Italy (US$135M), and Netherlands (US$115M). In the same year, the main importing countries for Estrogens and Progestins were Netherlands (US$73.8M), Italy (US$66.7M), and United States (US$64.5M).